PHARMANUTRA SPA (PHN.MI) Stock Fundamental Analysis
Europe - Euronext Milan - BIT:PHN - IT0005274094 - Common Stock
57 EUR
+0.2 (+0.35%)
PHN gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 15 industry peers in the Personal Care Products industry. Both the health and profitability get an excellent rating, making PHN a very profitable company, without any liquidiy or solvency issues. PHN is valued quite expensive, but it does show an excellent growth. With these ratings, PHN could be worth investigating further for growth and quality investing!.
1. Profitability
1.1 Basic Checks
PHN had positive earnings in the past year.
PHN had a positive operating cash flow in the past year.
PHN had positive earnings in each of the past 5 years.
PHN had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of 20.41%, PHN belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
PHN has a better Return On Equity (38.54%) than 100.00% of its industry peers.
With an excellent Return On Invested Capital value of 26.24%, PHN belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for PHN is significantly above the industry average of 11.60%.
The 3 year average ROIC (17.21%) for PHN is below the current ROIC(26.24%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.41% | ||
| ROE | 38.54% | ||
| ROIC | 26.24% |
ROA(3y)13.53%
ROA(5y)17.42%
ROE(3y)26.61%
ROE(5y)29.54%
ROIC(3y)17.21%
ROIC(5y)18.21%
1.3 Margins
Looking at the Profit Margin, with a value of 13.48%, PHN is in the better half of the industry, outperforming 80.00% of the companies in the same industry.
PHN's Profit Margin has declined in the last couple of years.
PHN has a Operating Margin of 21.87%. This is amongst the best in the industry. PHN outperforms 100.00% of its industry peers.
PHN's Operating Margin has been stable in the last couple of years.
The Gross Margin of PHN (97.04%) is better than 100.00% of its industry peers.
In the last couple of years the Gross Margin of PHN has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 21.87% | ||
| PM (TTM) | 13.48% | ||
| GM | 97.04% |
OM growth 3Y-4.84%
OM growth 5Y1.01%
PM growth 3Y-10.74%
PM growth 5Y-1.82%
GM growth 3Y-0.75%
GM growth 5Y-0.04%
2. Health
2.1 Basic Checks
PHN has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
The number of shares outstanding for PHN remains at a similar level compared to 1 year ago.
PHN has less shares outstanding than it did 5 years ago.
The debt/assets ratio for PHN has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 9.80 indicates that PHN is not in any danger for bankruptcy at the moment.
PHN has a Altman-Z score of 9.80. This is amongst the best in the industry. PHN outperforms 100.00% of its industry peers.
PHN has a debt to FCF ratio of 2.70. This is a good value and a sign of high solvency as PHN would need 2.70 years to pay back of all of its debts.
With a decent Debt to FCF ratio value of 2.70, PHN is doing good in the industry, outperforming 73.33% of the companies in the same industry.
PHN has a Debt/Equity ratio of 0.28. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.28, PHN is in the better half of the industry, outperforming 66.67% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.28 | ||
| Debt/FCF | 2.7 | ||
| Altman-Z | 9.8 |
ROIC/WACC3.34
WACC7.85%
2.3 Liquidity
PHN has a Current Ratio of 2.06. This indicates that PHN is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.06, PHN belongs to the top of the industry, outperforming 93.33% of the companies in the same industry.
A Quick Ratio of 1.75 indicates that PHN should not have too much problems paying its short term obligations.
With an excellent Quick ratio value of 1.75, PHN belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.06 | ||
| Quick Ratio | 1.75 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 20.20% over the past year.
Measured over the past years, PHN shows a quite strong growth in Earnings Per Share. The EPS has been growing by 14.63% on average per year.
PHN shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 15.06%.
PHN shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 16.59% yearly.
EPS 1Y (TTM)20.2%
EPS 3Y6.71%
EPS 5Y14.63%
EPS Q2Q%3.36%
Revenue 1Y (TTM)15.06%
Revenue growth 3Y19.25%
Revenue growth 5Y16.59%
Sales Q2Q%10.35%
3.2 Future
The Earnings Per Share is expected to grow by 14.67% on average over the next years. This is quite good.
The Revenue is expected to grow by 14.07% on average over the next years. This is quite good.
EPS Next Y5.49%
EPS Next 2Y12.76%
EPS Next 3Y14.67%
EPS Next 5YN/A
Revenue Next Year14.06%
Revenue Next 2Y14.68%
Revenue Next 3Y15.27%
Revenue Next 5Y14.07%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 23.27 indicates a rather expensive valuation of PHN.
PHN's Price/Earnings ratio is in line with the industry average.
When comparing the Price/Earnings ratio of PHN to the average of the S&P500 Index (26.37), we can say PHN is valued inline with the index average.
With a Price/Forward Earnings ratio of 23.57, PHN is valued on the expensive side.
Based on the Price/Forward Earnings ratio, PHN is valued a bit more expensive than 60.00% of the companies in the same industry.
PHN is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 36.20, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 23.27 | ||
| Fwd PE | 23.57 |
4.2 Price Multiples
PHN's Enterprise Value to EBITDA ratio is a bit more expensive when compared to the industry. PHN is more expensive than 66.67% of the companies in the same industry.
80.00% of the companies in the same industry are cheaper than PHN, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 67.36 | ||
| EV/EBITDA | 12.92 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
The excellent profitability rating of PHN may justify a higher PE ratio.
A more expensive valuation may be justified as PHN's earnings are expected to grow with 14.67% in the coming years.
PEG (NY)4.24
PEG (5Y)1.59
EPS Next 2Y12.76%
EPS Next 3Y14.67%
5. Dividend
5.1 Amount
PHN has a Yearly Dividend Yield of 1.75%. Purely for dividend investing, there may be better candidates out there.
Compared to an average industry Dividend Yield of 2.84, PHN has a dividend in line with its industry peers.
Compared to the average S&P500 Dividend Yield of 2.32, PHN is paying slightly less dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.75% |
5.2 History
The dividend of PHN is nicely growing with an annual growth rate of 11.21%!
Dividend Growth(5Y)11.21%
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
PHN pays out 40.63% of its income as dividend. This is a bit on the high side, but may be sustainable.
PHN's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP40.63%
EPS Next 2Y12.76%
EPS Next 3Y14.67%
BIT:PHN (12/3/2025, 7:00:00 PM)
57
+0.2 (+0.35%)
Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupHousehold & Personal Products
GICS IndustryPersonal Care Products
Earnings (Last)
Earnings (Next)
Inst Owners17.08%
Inst Owner ChangeN/A
Ins Owners65.02%
Ins Owner ChangeN/A
Market Cap551.76M
Revenue(TTM)175.08M
Net Income(TTM)23.61M
Analysts82.86
Price Target82.62 (44.95%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.75% |
Yearly Dividend0.85
Dividend Growth(5Y)11.21%
DP40.63%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.53%
PT rev (3m)2.53%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-3.09%
EPS NY rev (3m)-6.95%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.05%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 23.27 | ||
| Fwd PE | 23.57 | ||
| P/S | 3.15 | ||
| P/FCF | 67.36 | ||
| P/OCF | 44.77 | ||
| P/B | 9.01 | ||
| P/tB | 14.78 | ||
| EV/EBITDA | 12.92 |
EPS(TTM)2.45
EY4.3%
EPS(NY)2.42
Fwd EY4.24%
FCF(TTM)0.85
FCFY1.48%
OCF(TTM)1.27
OCFY2.23%
SpS18.09
BVpS6.33
TBVpS3.86
PEG (NY)4.24
PEG (5Y)1.59
Graham Number18.68
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.41% | ||
| ROE | 38.54% | ||
| ROCE | 45.24% | ||
| ROIC | 26.24% | ||
| ROICexc | 32.19% | ||
| ROICexgc | 49.25% | ||
| OM | 21.87% | ||
| PM (TTM) | 13.48% | ||
| GM | 97.04% | ||
| FCFM | 4.68% |
ROA(3y)13.53%
ROA(5y)17.42%
ROE(3y)26.61%
ROE(5y)29.54%
ROIC(3y)17.21%
ROIC(5y)18.21%
ROICexc(3y)25.61%
ROICexc(5y)33.67%
ROICexgc(3y)43.23%
ROICexgc(5y)50.61%
ROCE(3y)29.76%
ROCE(5y)31.61%
ROICexgc growth 3Y-15.98%
ROICexgc growth 5Y-10.26%
ROICexc growth 3Y-20.69%
ROICexc growth 5Y-11.75%
OM growth 3Y-4.84%
OM growth 5Y1.01%
PM growth 3Y-10.74%
PM growth 5Y-1.82%
GM growth 3Y-0.75%
GM growth 5Y-0.04%
F-Score7
Asset Turnover1.51
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.28 | ||
| Debt/FCF | 2.7 | ||
| Debt/EBITDA | 0.4 | ||
| Cap/Depr | 97.13% | ||
| Cap/Sales | 2.36% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 28.97% | ||
| Profit Quality | 34.7% | ||
| Current Ratio | 2.06 | ||
| Quick Ratio | 1.75 | ||
| Altman-Z | 9.8 |
F-Score7
WACC7.85%
ROIC/WACC3.34
Cap/Depr(3y)763.09%
Cap/Depr(5y)544.05%
Cap/Sales(3y)14.97%
Cap/Sales(5y)11.04%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20.2%
EPS 3Y6.71%
EPS 5Y14.63%
EPS Q2Q%3.36%
EPS Next Y5.49%
EPS Next 2Y12.76%
EPS Next 3Y14.67%
EPS Next 5YN/A
Revenue 1Y (TTM)15.06%
Revenue growth 3Y19.25%
Revenue growth 5Y16.59%
Sales Q2Q%10.35%
Revenue Next Year14.06%
Revenue Next 2Y14.68%
Revenue Next 3Y15.27%
Revenue Next 5Y14.07%
EBIT growth 1Y14.83%
EBIT growth 3Y13.47%
EBIT growth 5Y17.77%
EBIT Next Year22.06%
EBIT Next 3Y16.37%
EBIT Next 5Y9.97%
FCF growth 1Y144.25%
FCF growth 3Y1.75%
FCF growth 5Y17.94%
OCF growth 1Y38.33%
OCF growth 3Y0.14%
OCF growth 5Y11.34%
PHARMANUTRA SPA / PHN.MI FAQ
What is the fundamental rating for PHN stock?
ChartMill assigns a fundamental rating of 7 / 10 to PHN.MI.
What is the valuation status for PHN stock?
ChartMill assigns a valuation rating of 2 / 10 to PHARMANUTRA SPA (PHN.MI). This can be considered as Overvalued.
How profitable is PHARMANUTRA SPA (PHN.MI) stock?
PHARMANUTRA SPA (PHN.MI) has a profitability rating of 8 / 10.
Can you provide the financial health for PHN stock?
The financial health rating of PHARMANUTRA SPA (PHN.MI) is 8 / 10.
How sustainable is the dividend of PHARMANUTRA SPA (PHN.MI) stock?
The dividend rating of PHARMANUTRA SPA (PHN.MI) is 4 / 10 and the dividend payout ratio is 40.63%.